Navigation Links
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
Date:9/24/2008

-responders encouraged InterMune and Roche to continue their plans to aggressively study ITMN-191 in this difficult to treat population and provided an important insight to the range of doses to explore in future studies.

-- Pharmacokinetic (pk) and Pharmacodynamic (pd) Results in the Phase 1b MAD Study (Poster #1861): ITMN-191 was intentionally designed to achieve a high liver-to-plasma ratio in HCV patients in order to reduce any potential side effects associated with systemic circulation of drug. Poster #1861 shows that the strong viral kinetic results reported in abstract #1847 were associated with very low plasma concentrations, achieving the key objective of a high liver-to-plasma ratio in patients infected with HCV. The pharmacokinetics of ITMN-191 in mono-therapy were more than dose proportional at higher doses.

Results of In Vitro Combinations of ITMN-191 plus direct anti-virals in HCV models

-- Two Experiments of the Combination of ITMN-191 with HCV Polymerase Inhibitors R7128 and R1626 (Poster #1885): ITMN-191 was combined separately with two polymerase inhibitors, R7128 (Roche/Pharmasset) and R1626 (Roche) in two assays. One assay modeled HCV replication (14-day replicon clearance assay) and the other assay modeled viral resistance (a 3-week colony formation assay model). The combination of ITMN-191 with the active moeity of either R7128 or R1626 resulted in significantly enhanced clearance of the HCV replicon and reduced or suppressed the emergence of drug-resistant viral variants.

This work was carried out in anticipation of future clinical studies using ITMN-191 with either R7128 or R1626, and demonstrates that such combinations would likely result in significantly greater antiviral activity than has been observed with any of these agents in previous monotherapy trials.

Current Development of ITMN-191

Based on the encouraging results reported in the above studies, in late May 2008 InterMune initiated an ongoin
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
2. InterMune to Present at Canaccord Adams Conference
3. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
4. InterMune to Present at BMO Healthcare Conference
5. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
6. InterMune to Present at Jefferies Healthcare Conference
7. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
8. InterMune to Present at Citigroup Healthcare Conference
9. InterMune to Present at Bank of America Health Care Conference
10. InterMune to Present at Deutsche Bank Health Care Conference
11. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... NEW YORK , Aug. 21, 2014 /PRNewswire/ ... OTCM) congratulates Immune Pharmaceuticals Inc., a biotechnology company, ... Capital Market.  Immune previously traded on OTCQX®, the ... operated by OTC Markets Group. Logo - ... Immune Pharmaceuticals on the successful execution of its ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pursuit ... selling optimization technology and services for Life Sciences ... “Grading Pharma’s Use of New Commercial Sales Models” ... & Analytics. , The article examines some innovative ... that are being tested in the pharmaceutical market. ...
(Date:8/21/2014)... 21, 2014 SoundConnect , ... recognized as one of the nation’s Fastest Growing ... for the 2nd consecutive year. Inc. magazine today ... Inc. 500|5000, an exclusive ranking of the nation's ... comprehensive look at the most important segment of ...
(Date:8/20/2014)... of patented university inventions licensed to biotechnology firms ... commercialization. To open these roadblocks, the researchers suggest ... the discovery stage could lead to faster commercialization ... derived from discoveries made in university laboratories and ... during clinical trials, which have a high failure ...
Breaking Biology Technology:OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... , , ... May 11 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ... for the treatment of cancer, today announced the dosing of the ... with SL052 Photodynamic Therapy in prostate cancer patients. The study will ...
... HARBIN, China , May 11 /PRNewswire-Asia-FirstCall/ -- ... Company") (Nasdaq: CSKI ), a leading,fully integrated pharmaceutical company ... ("PRC"), today announced the Company attended,the 107th China Import and ... May 1st,to 5th, 2010 and generated significant interest from ...
... N30 Pharma (N30), a biopharmaceutical company focused on the discovery and development of ... that it has completed a $10 million financing and expanded its Board ... Joining the Company,s Board of Directors ... , , ...
Cached Biology Technology:Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial 2Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial 3China Sky One Medical Attended Import and Export Fair to Enhance International Growth Opportunity 2China Sky One Medical Attended Import and Export Fair to Enhance International Growth Opportunity 3China Sky One Medical Attended Import and Export Fair to Enhance International Growth Opportunity 4
(Date:8/21/2014)... North Carolina State University have developed a novel and ... has applications for creating new materials as well as ... new technique allows us to model much larger and ... more quickly," says Nan Li, lead author of a ... NC State,s Department of Materials Science and Engineering. "This ...
(Date:8/20/2014)... study of 158 pregnant teenagers in Rochester, NY, nearly ... consumption of ice, cornstarch, vacuum dust, baby powder and ... study. , Moreover, such teens had significantly lower iron ... nonfood substances. , Pregnant teens, regardless of pica, are ... to iron deficiency and anemia. Low iron in pregnant ...
(Date:8/20/2014)... 20, 2014 /CNW/ -  Issue Serious ... quickly become life threatening for some children.    ... million Canadians have food allergies and this number may be ... children are estimated to have food allergies.  ... irritations and hives to breathing difficulties and loss of consciousness. ...
Breaking Biology News(10 mins):Researchers develop models to study polyelectrolytes, including DNA and RNA 2Pica in pregnant teens linked to low iron 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3
... R.I. [Brown University] Scientists have long known that ... clear is how the brain processes more complex and ... 28, 2010) in the journal Neuron , a ... of CaliforniaBerkeley tested whether the frontal lobe has the ...
... divided into three sessions: the past, present and future ... and ethics related to PGD. The target audience ... physicians, nurses, embryologists, patient advocacy groups and patients themselves. ... event here: http://www.eshre.eu/page.aspx/905 You are welcome ...
... released this week in The Lancet Infectious Diseases ... a bacterial infection that causes pneumonia, meningitis and sepsis ... disease, a blood disorder prevalent in African children that ... The study underscores the critical need for use of ...
Cached Biology News:Complex brain functions help adapt to new situations and stimuli 2Vaccines preventing pneumococcal disease protect African children with sickle-cell disease 2Vaccines preventing pneumococcal disease protect African children with sickle-cell disease 3
UBC13 Antibody...
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
Phenytoin-BSA Isolated IgY DFc Drug...
Tropomyosin 4 [Tm4]...
Biology Products: